ANI Pharmaceuticals Reports Record 2025 Results, Reaffirms Strong 2026 Guidance Driven by Rare Disease Growth

summarizeSummary

ANI Pharmaceuticals reported record fourth quarter and full year 2025 financial results, driven by strong growth in its Rare Disease segment, particularly Cortrophin Gel, and reaffirmed its robust 2026 financial guidance.

check_boxKey Events

• Record 2025 Financial Performance

  Reported record quarterly net revenues of $247.1 million (up 29.6% year-over-year) and full year net revenues of $883.4 million (up 43.8% year-over-year). GAAP net income available to common shareholders was $27.5 million for Q4 and $77.2 million for the full year, a significant improvement from prior year losses.

• Strong Rare Disease Segment Growth

  Total Rare Disease net revenue increased 50.8% in Q4 to $131.3 million and 84.1% for the full year to $422.6 million. Cortrophin Gel net revenues surged 87.6% in Q4 to $111.4 million and 75.6% for the full year to $347.8 million, driven by record new patient starts and expanded sales force efforts.

• Reaffirmed Robust 2026 Financial Guidance

  The company reaffirmed its full year 2026 guidance, projecting total net revenues between $1,055 million and $1,115 million (19-26% growth) and adjusted non-GAAP EBITDA between $275 million and $290 million (20-26% growth). Cortrophin Gel net revenue is expected to grow 55-65%.

• Strategic Focus on Rare Disease Expansion

  ANI is accelerating its transformation into a leading Rare Disease company, with Rare Disease expected to represent approximately 60% of total revenue in 2026. A planned expansion of its Rare Disease organization by approximately 90 people is underway to target acute gouty arthritis flares for Cortrophin Gel.

auto_awesomeAnalysis

ANI Pharmaceuticals delivered exceptional financial performance in 2025, achieving record revenues and a significant turnaround from a GAAP net loss to substantial net income. This growth was primarily fueled by its Rare Disease business, with Cortrophin Gel showing remarkable year-over-year revenue increases. The reaffirmation of strong 2026 guidance, projecting continued double-digit revenue and EBITDA growth, underscores management's confidence in its strategic transformation into a leading Rare Disease company. Investors should note the planned expansion of the Rare Disease organization to further capitalize on the Cortrophin Gel opportunity in acute gouty arthritis flares. This report signals strong operational execution and a positive outlook for future growth.